TEVIMBRA, the PD-1 drug from BeiGene, has recently achieved another milestone with the approval of a new indication, extending its impact in cancer treatment. As the pharmaceutical world continues to innovate, TEVIMBRA’s winning streak has set it apart, offering competition to well-established PD-1 drugs like Keytruda. This article highlights TEVIMBRA’s growing role in oncology, its… Read.